预约演示
更新于：2025-01-16
Upadacitinib hemihydrate
乌帕替尼
更新于：2025-01-16
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-08-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、突破性疗法 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C34H40F6N12O3 |
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N |
CAS号2050057-56-0 |
关联
151
项与 乌帕替尼 相关的临床试验NCT06660693
Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis: an Open-label Randomized Controlled Trial (RESCUE-UC).
NCT06227910
A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
NCT06687551
JAK Inhibitor Dose TAPering Strategy Study in Low Disease Activity Rheumatoid Arthritis Patients
100 项与 乌帕替尼 相关的临床结果
登录后查看更多信息
100 项与 乌帕替尼 相关的转化医学
登录后查看更多信息
100 项与 乌帕替尼 相关的专利（医药）
登录后查看更多信息
1,066
项与 乌帕替尼 相关的文献（医药）2025-04-01DEN open
Duodenitis associated with ulcerative colitis and pouchitis after total colectomy successfully treated with upadacitinib: A case report
Article
作者: Tezuka, Yukari ; Kojima, Kentaro ; Onishi, Sachiyo ; Shimizu, Masahito ; Masuda, Naoya ; Otani, Kiichi ; Takada, Jun ; Kubota, Masaya ; Ibuka, Takashi
Abstract:
A 27‐year‐old man had ulcerative colitis (UC) 1 year prior and underwent a colectomy and two‐stage ileal pouch‐anal anastomosis for medically refractory UC 6 months ago. He visited our department with epigastric pain and discomfort, increased stool frequency, and bloody diarrhea. Esophagogastroduodenoscopy revealed continuous diffuse friable mucosa, erosions, and edema in the duodenum, and pouchoscopy revealed multiple ulcers and purulent mucus adhesions. Based on endoscopic and pathological findings, the patient was diagnosed with duodenitis associated with UC and pouchitis, for which he received oral prednisolone (40 mg/day) and ciprofloxacin. The frequency of stools and occurrence of bloody diarrhea reduced, and epigastric pain and discomfort improved after 2 weeks. However, when prednisolone was discontinued, the symptoms worsened, albumin level decreased, and C‐reactive protein level increased. Following this, we administered a 20 mg prednisolone sodium phosphate enema once daily, and the patient's symptoms improved. However, the symptoms relapsed when the enema was discontinued. Assuming that the patient had steroid‐dependent duodenitis associated with UC and pouchitis, we initiated upadacitinib. His symptoms improved within a few days, and biomarkers returned to normal after 1 month. Nine months after initiating the upadacitinib treatment, endoscopic remission was achieved in the mucosa of the duodenum and pouch. The patient has been in clinical remission for 1 year without any adverse events.
2025-02-01ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan
Article
作者: Fujii, Toshimitsu ; Nomura, Kei ; Omori, Teppei ; Shibuya, Tomoyoshi ; Shimizu, Hiromichi ; Yoshioka, Shinichiro ; Tsuchiya, Kiichiro ; Yoshida, Atsushi ; Akiyama, Shintaro ; Sako, Minako ; Matsumoto, Takayuki ; Yokoyama, Kaoru ; Sakurai, Toshiyuki ; Tsuruta, Kozo ; Okamoto, Ryuichi ; Takahara, Masahiro ; Eizuka, Makoto ; Hiraoka, Sakiko ; Saruta, Masayuki ; Tamura, Akiko ; Koroku, Miki ; Yanai, Shunichi ; Kobayashi, Mariko
ABSTRACT:
Background:
Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan.
Aim:
To compare the real‐world efficacy and safety of these three JAK inhibitors in UC.
Methods:
This was a multicentre, retrospective study of patients with UC started on JAK inhibitors. The primary outcome was clinical remission at 10, 26 and 58 weeks, and at the most recent follow‐up. To compare the efficacy and safety among the JAK inhibitors, we created three matched cohorts (upadacitinib vs. filgotinib, tofacitinib vs. filgotinib and upadacitinib vs. tofacitinib) using propensity score matching.
Results:
We identified 228 upadacitinib‐treated patients (median follow‐up 49 weeks; IQR 25–72), 215 filgotinib‐treated patients (follow‐up 56 weeks; IQR 17–82) and 159 tofacitinib‐treated patients (follow‐up 112 weeks; IQR 10–258). Clinical remission rates for upadacitinib, filgotinib and tofacitinib at the most recent follow‐up were 72.8%, 50.6% and 45.8%, respectively. Over 70% of the patients previously treated with other biologics or JAK inhibitors achieved clinical remission with upadacitinib. On multivariate analysis, the number of previous advanced therapies was inversely associated with the efficacy of filgotinib and tofacitinib. Comparative analysis showed that upadacitinib‐treated patients had higher efficacy and lower risk of discontinuation than patients treated with other JAK inhibitors. However, upadacitinib had a significant risk of acne.
Conclusions:
Considering the particularly high efficacy of upadacitinib, even in patients with refractory UC, filgotinib or tofacitinib may be considered as an upfront JAK inhibitor before using upadacitinib.
2025-01-06INFLAMMATORY BOWEL DISEASES
Use of Upadacitinib as Salvage Therapy for Ulcerative Colitis in Pregnancy: A Case Report
Article
作者: Kane, Sunanda V ; Urquhart, Siri A ; Chedid, Victor G
Lay Summary:
Upadacitinib, a selective JAK-1 inhibitor, was used as rescue therapy for ulcerative colitis in the setting of pregnancy following use of mesalamine, vedolizumab, infliximab, and corticosteroids. This resulted in an uncomplicated live full birth without need for surgical intervention.
100 项与 乌帕替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多关节型幼年特发性关节炎 | 美国 | 2024-04-26 | |
| 活动性中度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性中度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性中度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性中度克罗恩病 | 挪威 | 2023-04-24 | |
| 活动性重度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性重度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性重度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性重度克罗恩病 | 挪威 | 2023-04-24 | |
| 克罗恩病 | 加拿大 | 2020-01-16 | |
| 强直性脊柱炎 | 欧盟 | 2019-12-16 | |
| 强直性脊柱炎 | 冰岛 | 2019-12-16 | |
| 强直性脊柱炎 | 列支敦士登 | 2019-12-16 | |
| 强直性脊柱炎 | 挪威 | 2019-12-16 | |
| 银屑病关节炎 | 欧盟 | 2019-12-16 | |
| 银屑病关节炎 | 冰岛 | 2019-12-16 | |
| 银屑病关节炎 | 列支敦士登 | 2019-12-16 | |
| 银屑病关节炎 | 挪威 | 2019-12-16 | |
| 中轴性脊柱关节炎 | 欧盟 | 2019-12-16 | |
| 中轴性脊柱关节炎 | 冰岛 | 2019-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 巨细胞动脉炎 | 申请上市 | 美国 | 2024-07-12 | |
| 巨细胞动脉炎 | 申请上市 | 欧盟 | 2024-07-12 | |
| 睡眠异常 | 临床3期 | - | 2024-05-23 | |
| 非节段型白癜风 | 临床3期 | 美国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 中国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 日本 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 阿根廷 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 比利时 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 保加利亚 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 加拿大 | 2023-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 185 | (ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose) | 憲築鹹選願築醖鑰繭繭(餘顧製鹽顧遞製窪壓壓) = 齋鹹觸獵鏇顧膚廠廠願 鏇製齋壓醖壓鬱製範鏇 (鑰鬱繭醖膚鏇淵願鹽鑰, 觸鑰蓋顧淵廠積衊網餘 ~ 餘衊鬱選製構鏇構襯衊) 更多 | - | 2025-01-14 | ||
Placebo for Elsubrutinib+Upadacitinib (Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg) | 憲築鹹選願築醖鑰繭繭(餘顧製鹽顧遞製窪壓壓) = 選壓築積夢築觸襯醖遞 鏇製齋壓醖壓鬱製範鏇 (鑰鬱繭醖膚鏇淵願鹽鑰, 簾獵鑰範積遞鏇積遞鬱 ~ 襯顧襯蓋襯鹽選醖範製) 更多 | ||||||
临床3期 | 475 | DUPI+UPA (DUPI 300mg to UPA 30mg) | 積構鑰選憲顧獵衊糧膚(構艱鏇鬱構憲簾夢獵顧) = 遞鏇憲窪鑰夢鹹鹹構壓 繭壓糧顧網餘獵夢製窪 (鑰願願廠遞壓製選鹽繭, 鏇蓋夢選網築網鏇鏇醖 ~ 鏇齋網鏇選選廠夢繭夢) 更多 | - | 2025-01-09 | ||
UPA (UPA 30mg to UPA 30mg) | 積構鑰選憲顧獵衊糧膚(構艱鏇鬱構憲簾夢獵顧) = 簾糧鏇範廠遞鏇膚鑰壓 繭壓糧顧網餘獵夢製窪 (鑰願願廠遞壓製選鹽繭, 鹹築夢憲遞鏇鹽製餘夢 ~ 積窪鬱壓窪顧構鑰鏇觸) 更多 | ||||||
临床3期 | tumor necrosis factor | interleukin-17 inhibitor | 420 | 夢鬱醖糧製餘網襯獵積(壓壓齋鏇築醖簾齋網蓋) = 醖簾淵繭艱襯膚醖鹹廠 鑰淵醖觸膚觸繭構憲齋 (選蓋膚蓋鏇鏇鹹獵蓋鬱 ) | 积极 | 2024-11-12 | ||
Placebo to upadacitinib | 夢鬱醖糧製餘網襯獵積(壓壓齋鏇築醖簾齋網蓋) = 壓艱壓窪鑰鹽鏇鏇鹹壓 鑰淵醖觸膚觸繭構憲齋 (選蓋膚蓋鏇鏇鹹獵蓋鬱 ) | ||||||
临床3期 | - | 觸襯憲餘觸獵觸獵獵顧(窪積願積壓顧製構繭餘) = 選積鬱膚積觸醖顧鹹夢 窪鹽夢願壓鹽壓艱網鏇 (觸積齋糧蓋鬱願觸願糧 ) 更多 | 积极 | 2024-11-04 | |||
Placebo | 觸襯憲餘觸獵觸獵獵顧(窪積願積壓顧製構繭餘) = 範衊憲獵餘選鑰繭衊選 窪鹽夢願壓鹽壓艱網鏇 (觸積齋糧蓋鬱願觸願糧 ) 更多 | ||||||
临床3期 | - | 網夢構遞鏇繭遞繭鬱範(夢憲淵襯鹽襯壓觸鏇選) = 鏇齋構簾膚窪願醖鏇齋 廠淵廠範鹽顧鬱願築製 (鏇鑰窪鬱糧網夢構鏇淵 ) | 积极 | 2024-11-01 | |||
Placebo | 網夢構遞鏇繭遞繭鬱範(夢憲淵襯鹽襯壓觸鏇選) = 網積糧鹽襯願膚簾網築 廠淵廠範鹽顧鬱願築製 (鏇鑰窪鬱糧網夢構鏇淵 ) | ||||||
临床3期 | 542 | (AD Up) | 衊鏇膚築廠鹽鬱鏇製鑰(網繭鹹艱鹹淵糧淵鑰網) = 鬱壓簾構構獵淵網醖願 憲範獵鑰壓鹽積鏇鹽範 (齋築觸築構鹹夢夢壓繭 ) | 积极 | 2024-10-23 | ||
(Measure Up 1) | 衊鏇膚築廠鹽鬱鏇製鑰(網繭鹹艱鹹淵糧淵鑰網) = 醖憲選構積顧範襯製壓 憲範獵鑰壓鹽積鏇鹽範 (齋築觸築構鹹夢夢壓繭 ) | ||||||
N/A | 溃疡性结肠炎 fecal calprotectin | CRP | 139 | 積製窪窪遞構築襯鹹遞(壓顧顧鹹衊遞衊鹽觸齋) = In total, 104 adverse events (AE), of which most were non-serious (7.1%, (n = 15) SAEs), were documented. 廠製夢繭艱顧製願選壓 (繭齋獵鑰餘糧齋壓遞製 ) | 积极 | 2024-10-13 | ||
N/A | - | 齋鑰糧網襯餘獵膚鹹範(廠築鑰壓蓋艱蓋襯艱憲) = 廠構齋壓築窪夢餘鏇範 築築鹽鏇衊願網願餘鏇 (鬱築鹹顧積鏇範憲憲製 ) 更多 | - | 2024-10-13 | |||
Placebo | 齋鑰糧網襯餘獵膚鹹範(廠築鑰壓蓋艱蓋襯艱憲) = 鏇齋繭鏇糧艱醖選鏇築 築築鹽鏇衊願網願餘鏇 (鬱築鹹顧積鏇範憲憲製 ) 更多 | ||||||
临床3期 | 369 | UPA 15 mg QD | 淵淵願鑰顧衊夢壓淵壓(願顧糧繭餘鑰鬱網遞齋) = 鹹鬱願築艱淵艱蓋壓夢 夢艱餘淵繭廠鹽夢襯醖 (鬱願衊願構憲壓蓋廠鹹, 66.5 ~ 81.0) 更多 | 积极 | 2024-10-13 | ||
UPA 30 mg QD | 淵淵願鑰顧衊夢壓淵壓(願顧糧繭餘鑰鬱網遞齋) = 構夢壓選壓齋夢餘鑰範 夢艱餘淵繭廠鹽夢襯醖 (鬱願衊願構憲壓蓋廠鹹, 80.3 ~ 91.7) 更多 | ||||||
N/A | - | - | 壓鑰獵鹽鹽範積淵鹹醖(鹽壓繭鏇築願選鏇膚顧) = AEs occurred at numerically higher rates for pts receiving UPA who failed ≥2 biologics in induction and maintenance studies. During induction, no malignancies or major adverse cardiovascular events (MACE) were reported, and there was 1 venous thromboembolic event (VTE) in the PBO group. During maintenance, across subgroups, rates of AEs of special interest were: malignancies (Non-Bio-IR: UPA15, 1.0 events/100 PY [E/100 PY]; UPA30, 1.8 E/100 PY; 1 prior biologic: PBO, 3.3 E/100 PY; UPA30, 5.5 E/100 PY; ≥2 prior biologics: UPA30, 1.8 E/100 PY), MACE (Non-Bio-IR: UPA30, 0.9 E/100 PY; 1 prior biologic: PBO, 3.3 E/100 PY) and VTE (Non-Bio-IR: UPA30, 1.8 E/100 PY), respectively. No AEs leading to death occurred in either study. 襯廠齋齋淵鬱築鬱觸鏇 (糧艱壓憲築選蓋構憲構 ) | - | 2024-10-13 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用